INTRODUCTION
============

Thyroid nodules are common worldwide, and the prevalence of palpable thyroid nodules is 4-7% among adult populations.[@B1][@B2] With the increased usage of ultrasound (US) in medical practice, an increasing number of nonpalpable thyroid nodules are detected in 20-67% of the general population.[@B3][@B4] The majority of patients with thyroid nodules can be managed over time, justifying efforts to select better candidates for thyroidectomy, because approximately 5% of thyroid nodules may have malignancy.[@B5][@B6] Many studies have suggested US criteria that could be used to determine malignancy from benign lesions,[@B7][@B8] although none of them have shown significant impact on clinical practice, despite the wide acceptance and usefulness of the suggested criteria.[@B9]

Fine-needle aspiration biopsy (FNAB) is considered to be the best diagnostic tool for determining malignant from benign nodules. However, FNAB also has a relatively high false-negative rate, ranging from 0.7 to 21%.[@B10][@B11][@B12] This often leads to a question of whether a repeat aspiration should be performed or whether follow-up with US should be performed on suspicious thyroid nodules.[@B13][@B14]

US findings of lymphocytic thyroiditis or Hashimoto\'s thyroiditis show diffusely coarse and heterogeneous hypoechogenicity.[@B15][@B16][@B17] However, lymphocytic thyroiditis can be observed as a focal thyroid nodule that appears to be hypoechoic with ill-defined margins: an appearance that is indistinguishable from that of a malignant nodule ([Fig. 1](#F1){ref-type="fig"}).[@B5][@B18][@B19] Therefore, we sought to identify clinical and biochemical findings, in addition to US features, that could be used to determine focal lymphocytic thyroiditis from thyroid malignancy in order to reduce the need for repetitive FNABs.

MATERIALS AND METHODS
=====================

Patients
--------

We retrospectively reviewed the medical records of 214 patients who had thyroid nodules with suspicious features for malignancy and had undergone US-guided FNAB between January 2005 and December 2010 at Severance Hospital, Seoul, Korea. First, we selected 55 patients (mean age, 54.1 years; range, 26-74 years) who were diagnosed with focal lymphocytic thyroiditis (FLT), and 59 patients (mean age, 54.4 years; range, 28-77 years) diagnosed with adenomatous hyperplasia (AH) by two or more repeat FNABs on thyroid nodules with suspicious features for malignancy on US. Then we selected 100 papillary thyroid cancer (PTC) patients who were diagnosed based on surgical pathology after the initial US-guided FNAB, matched for sex and age±5 (mean age, 52.5 years; range, 29-82 years) with the FLT group or the AH group. We retrospectively reviewed the US, cytological, and pathological results of the patients. Hashimoto\'s thyroiditis is widely known and defined as elevated thyrotropin (TSH), as well as antithyroid peroxidase antibody (TPO-Ab) positivity and/or antithyroglobulin antibody (Tg-Ab) positivity in serum. Only 1 patient with PTC and 2 patients with AH received treatment for thyroid diseases with levothyroxine, and among 4 patients who had FLT, three were treated with levothyroxine and one with methimazole.

Laboratory and imaging tests
----------------------------

Thyroid functions were measured by radioimmunoassay using T3-CTK (Diasorin SpA, Saluggia, Italy) for T3 and Amerlex-MAB^\*^ FT4 kit (Trinity Biotech PLC, Wicklow, Ireland) for free T4. Serum TSH level was determined by immunoradiometric assay using TSH-CTK-3 kit (Diasorin SpA, Saluggia, Italy). The reference ranges were 98-180 ng/dL for T3, 0.73-1.95 ng/dL for FT4 and 0.3-4.0 µIU/mL for TSH. Serum anti-thyroglobulin (Tg-Ab) and thyroid peroxidase antibodies (TPO-Ab) were both determined by the Brahms RIA-Kit (BRAHMS AG, Hennigsdorf, Germany) and the reference ranges were 0-60 IU/mL.

US or US-guided FNAB were performed using a 5-12 MHz linear probe (iU22; Philips Medical Systems, Bothell, WA, USA), a 7-15 MHz linear probe (HDI 5000; Philips Medical Systems, Bothell, WA, USA), or an 8-15 MHz linear probe (Acuson Sequoia; Siemens Medical Solutions, Mountain View, CA, USA). Key features for \"suspicious for malignancy\" on US include microcalcification, irregular or microlobulated margin, hypoechogenicity, and taller than wide in shape (i.e., greater anteroposterior dimension than transverse dimension).[@B20][@B21] \"Diffuse thyroid disease\" (DTD) pattern was defined as diffusely heterogeneous hypoechogenicity on sonography.[@B22] US-guided FNAB was performed with a 23-gauge needle attached to a 20-mL disposable plastic syringe. Materials obtained from the aspiration biopsy were transferred onto glass slides and then placed immediately in 95% alcohol for Papanicolaou staining. AH was diagnosed if the cytology revealed the presence of colloids and varying numbers of follicular cells, and lymphocytic thyroiditis was diagnosed if there were follicular cells with scattered background lymphocytes.[@B5][@B23]

Statistical analysis
--------------------

All statistical analysis was performed using PASW v. 18.0 for Windows (SPSS Inc., Chicago, IL, USA). Comparisons were performed by chi-square test or Fisher\'s exact test for categorical variables and Student t-test or Mann-Whitney U test for continuous variables. For multiple comparisons, the ANOVA with post hoc Bonferroni procedure was performed. To categorize serum TSH levels, we searched the best cut-off point for differentiating between PTC and FLT using receiver operating characteristic (ROC) curve analysis, which was 2.50 µIU/mL, with a sensitivity of 53% and specificity of 80%.

To differentiate between FLT and PTC, a logistic regression model with the backward stepwise method was used. The significant variables identified in an univariate analysis were subsequently entered into a multivariate analysis. In this model, the least statistically significant variables were removed one at a time until only independent variables with a preset *p* value≤ 0.1 were retained. All *p* values\<0.05 were considered significant.

RESULTS
=======

Baseline characteristics according to FLT, AH, and PTC
------------------------------------------------------

[Table 1](#T1){ref-type="table"} shows the clinical, biochemical, and US characteristics of the three groups. TSH levels and the frequency of Tg-Ab and TPO-Ab positivity were significantly different among the groups. In terms of US features, the proportions of taller than wide shape, calcification of nodules, and DTD pattern on US were significantly different among the groups. In comparisons between the FLT and PTC groups, as expected, TSH levels (*p*=0.014), Tg-Ab or TPO-Ab positivity (*p*\<0.001), and the proportions of patients taking thyroid medications (*p*=0.034) and having Hashimoto\'s thyroiditis (*p*\<0.001) were significantly higher in the FLT group than the PTC group. Among US features, absence of calcification (*p*=0.006) and DTD pattern on US (*p*\<0.001) were more frequently seen in the FLT group than the PTC group. The irregularity of margins, echogenicity, pattern of calcifications, and cystic degeneration in nodules did not differ between the FLT group and the PTC group. However, in comparisons between the AH group and the PTC group, nodule size was larger (*p*=0.029) and the proportion of a taller than wide shape of nodules was lower (*p*\<0.001) in the AH group than the PTC group.

Comparison between the FLT group and the PTC groups according to nodule size
----------------------------------------------------------------------------

Next, we evaluated whether differences in these variables between the FLT group and the PTC groups differed according to nodule size (\<10 mm or ≥10 mm) ([Table 2](#T2){ref-type="table"}). In terms of thyroid function, TSH levels were elevated in the FLT group, compared with the PTC group, regardless of nodules size. However, US features were different according to nodule size. In small nodules \<10 mm, the echogenicity of nodules (*p*=0.045) and DTD pattern on US (*p*\<0.001) differed significantly between the FLT group and the PTC groups. In contrast, among large nodules ≥10 mm, the FLT group showed a higher proportion of absence of calcification in thyroid nodules (*p*=0.010) and a DTD pattern on US (*p*=0.001) than the PTC group.

Univariate and multivariate analysis
------------------------------------

[Table 3](#T3){ref-type="table"} shows the odds ratio (OR) with 95% confidence interval (CI) for the characteristics more frequently seen in the FLT group or the AH group, compared with the PTC group, regardless of nodule size. On univariate analysis, the variables associated with FLT were TSH \>2.50 µIU/mL (OR=4.462, *p*\<0.001) and Tg-Ab (OR=9.118, *p*\<0.001) and TPO-Ab positivity (OR=4.136, *p*\< 0.001). Regarding US features, absence of calcification in nodules (OR=2.897, *p*=0.007) and presence of a DTD pattern on US (OR=36.231, *p*\<0.001) were associated with FLT rather than PTC. On multivariate analysis by the conditional backward method, Tg-Ab positivity, absence of calcification in nodules, and presence of a DTD pattern on US were significant. In contrast, nodules with a taller than wide shape showed significantly lower odds in prediction for AH in both univariate (OR=0.292, *p*=0.001) and multivariate (OR=0.288, *p*=0.001) analysis, suggesting that taller than wide shape is associated more with PTC rather than AH.

However, the variables associated with FLT were different according to nodule size ([Table 4](#T4){ref-type="table"}). In small nodules \<10 mm, Tg-Ab positivity (OR=4.985, *p*=0.027) and presence of a DTD pattern on US (OR=29.265, *p*\<0.001) were significantly associated with FLT in multivariate analysis. In contrast, absence of calcification (OR=12.487, *p*=0.042) and presence of a DTD pattern on US (OR=17.079, *p*=0.004) remained significant in large FLTs ≥10 mm.

Diagnostic predictor model to differentiate FLT from PTC
--------------------------------------------------------

To determine which variables can differentiate FLT from PTC, a standard set of predictive measures was calculated for each variable or the combination of all three variables of Tg-positivity, absence of calcification, and presence of a DTD pattern on US ([Table 5](#T5){ref-type="table"}). The presence of the DTD pattern on US showed, individually, the best specificity of 91% and positive predictive value (PPV) of 83%. In combination analysis of variables, the combination of three variables showed the best specificity of 99% and PPV of 96%, but a low sensitivity of 45%.

DISCUSSION
==========

Many studies have attempted to investigate a useful indicator of thyroid malignancy based on US findings. However, micronodules of lymphocytic thyroiditis can increase in size and be present hypoechoic or hyperechoic nodules with ill-defined margins on US.[@B5][@B18][@B19] Therefore, focal thyroiditis is indistinguishable from thyroid cancer or lymphoma. These so-called pseudotumors constituted 36% of the nodules of focal thyroiditis detected by US.[@B5] However, specific US features of focal thyroiditis are not well established.

In the present study, we aimed to identify the characteristics that would clearly distinguish FLT from malignancy, especially those showing suspicious features on US, and to make a diagnostic model for FLT. First, we grouped the patients according to diagnostic criteria by following cytologic confirmation of benign nodules, such as lymphocytic thyroiditis or AH by two or more FNABs. This is based on the previous reports that if the repeat cytological results were both \"benign\", the risk of malignancy was very low (3.1%).[@B7] Then, we compared clinical and biochemical parameters, in addition to US features, between FLT or AH and PTC.

Among US findings, nodules with a taller-than-wide shape was the only variable significantly different between AH and PTC in this study. This result is also consistent with previous studies that a taller-than-wide shape is the best predictor for malignancy.[@B21][@B24] In contrast, it is a task of great significance to identify the parameters to differentiate between FLT and PTC because many FLTs could have suspicious features on US. We found that the combination of three variables, including Tg-Ab positivity, absence of calcification in nodules, and presence of a DTD pattern on US, was the strongest predictor for FLT. However, the sensitivity was only 45%. This may be because absence of calcification in nodules had low specificity of 42% for FLT. Calcification has been noted in 23.8% of patients with focal thyroiditis, which is a greater concern for malignancy.[@B25] In the present study, 20% of FLTs had calcification, which could indicate malignancy. Therefore, absence or presence of calcification in nodules showed relatively low predictive value for FLT.

Lymphocytic thyroiditis shows diffuse heterogeneous hypoechogenicity on US, which appeared as a DTD pattern on US in our study. This feature is not specific to lymphocytic thyroiditis and may be observed in multinodular goiters, autoimmune thyroid disease, and subacute thyroiditis.[@B8][@B15][@B26] Although a DTD pattern on US is a nonspecific presentation for lymphocytic thyroiditis, a DTD pattern on US was the strongest predictor for FLT, individually, in the present study. It is less clear whether autoimmunity is the cause or effect of thyroid malignancy. In the present study, Tg-Ab positivity showed a significantly greater association with FLT than PTC. Meanwhile, TPO-Ab positivity was also associated with FLT in univariate analysis, but it was removed in multivariate analysis. Nevertheless, our results do not suggest that only seropositivity or seronegativity of Tg-Ab is correlated with PTC.

Recently, guidelines have recommended different managements based on nodule size.[@B20] Our study also showed different predictors for FLT according to nodule size. Based on our results, absence or presence of calcification in small nodules \<10 mm could not predict FLT or malignancy. Tg-Ab positivity and DTD pattern on US were only associated with small FLT.

There are several limitations in this study. First, selection bias was inevitable. Second, this study took samples from a small number of patients, because we selected patients who were diagnosed by two or more repeat FNABs. Third, we did not analyze intranodular vascularity, which has been shown to be associated with a risk of malignancy.[@B27]

In conclusion, suspicious thyroid nodules with benign cytologic results on initial FNAB could be followed-up with US, if there are seropositivity of Tg-Ab, no calcifications in nodules, and presence of a DTD pattern on US. Our study provides useful information as a tool for management decision making and to reduce the need for repetitive FNABs in thyroid nodules with discordant results between benign cytology and suspicious US features.
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![Examples of nodules suspected as malignant on US findings. (A) A 6-mm suspicious nodule (delineated by electronic *calipers*) was found on the right thyroid gland, and PTC was confirmed by surgical pathology. (B) A 7-mm suspicious nodule (delineated by electronic *calipers*) was found on the right thyroid gland and was cytologically confirmed as FLT more than twice by FNAB. The thyroid gland showed diffuse heterogeneous echogenicity, a characteristic finding of the DTD pattern of thyroid gland on US. (C) There was a 6-mm suspicious nodule (delineated by electronic *calipers*) on the left thyroid gland, which was cytologically confirmed as AH more than twice by FNAB. PTC, papillary thyroid cancer; FLT, focal lymphocytic thyroiditis; AH, adenomatous hyperplasia; FNAB, fine needle aspiration biopsy; DTD pattern, \"diffuse thyroid disease\" pattern on US; US, ultrasound.](ymj-56-1338-g001){#F1}

###### Baseline Characteristics According to Cytological Diagnosis
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                                             FLT (n=55)      AH (n=59)      PTC (n=100)   *p* value
  ------------------------------------------ --------------- -------------- ------------- -----------
  Clinical and biochemical characteristics                                                
   Age (yrs)                                 54.1±11.3       54.4±11.5      52.5±11.4     0.500
   Sex (male:female)                         4:51            3:56           8:92          0.782
   Current medications (%)^§^                4 (7.3)^\*^     2 (3.4)        1 (1.0)       0.110
   T3 (ng/dL)                                151.4±42.8      143.6±26.8     150.2±34.2    0.485
   FreeT4 (ng/dL)                            1.3±1.1         1.4±1.3        1.55±1.44     0.510
   TSH (µIU/mL)                              5.5±10.5^\*^    1.8±1.3        1.89±1.31     \<0.001
   Tg-Ab positive (%)                        33 (63.5)^‡^    7 (12.3)       16 (16.0)     \<0.001
   TPO-Ab positive (%)                       28 (53.8)^‡^    6 (10.7)       22 (22.0)     \<0.001
   Largest nodule diameter (mm)              7.5±4.7         10.1±6.5^\*^   8.9±4.9       0.035
   Hashimoto\'s thyroiditis (%)              28 (50.9)^‡^    3 (5.1)        9 (9.0)       \<0.001
  US characteristics                                                                      
   Shape                                                                                  
    Taller than wide                         28 (50.9)       16 (27.1)^‡^   56 (56)       0.002
    Wider than tall                          27 (49.1)       43 (72.9)      44 (44)       
   Margin                                                                                 
    Well-defined                             0 (0.0)         3 (5.1)        1 (1.0)       0.091
    Ill-defined                              55 (100.0)      56 (94.9)      99 (99.0)     
   Echogenicity                                                                           
    Marked hypoechoic                        5 (9.1)         1 (1.7)        4 (4.0)       0.352
    Hypoechoic                               45 (81.8)       54 (91.5)      91 (91.0)     
    Isoechoic                                3 (5.5)         1 (1.7)        2 (2.0)       
    Hyperechoic                              2 (3.6)         1 (1.7)        1 (1.0)       
    Mixed echoic                             0 (0.0)         2 (3.4)        2 (2.0)       
   Calcification                                                                          
    Absence                                  44 (80.0)^†∥^   29 (49.2)      58 (58.0)     0.005
    Micro                                    2 (3.6)         15 (25.4)      20 (20.0)     
    Macro                                    6 (11.0)        7 (11.8)       18 (18.0)     
    Mixed                                    2 (3.6)         6 (10.2)       4 (4.0)       
    Rim                                      1 (1.8)         2 (3.4)        0 (0.0)       
   Cystic degeneration                                                                    
    Present                                  0 (0.0)         0 (0.0)        2 (2.0)       0.316
    Absent                                   55 (100.0)      59 (100.0)     98 (98.0)     
   DTD pattern                                                                            
    Present                                  43 (78.2)^‡^    6 (10.2)       9 (9.0)       \<0.001
    Absent                                   12 (21.8)       53 (89.8)      91 (91.0)     

FLT, focal lymphocytic thyroiditis; AH, adenomatous hyperplasia; PTC, papillary thyroid cancer; US, ultrasound; DTD pattern, \"diffuse thyroid disease\" pattern on US; TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody.

Data are mean±SD or number of patients (%). *p* value by one-way ANOVA for continuous variables and χ^2^-test for categorical variables.

^\*^*p*\<0.05, ^†^*p*\<0.01, ^††^*p*\<0.001, the comparison of the FLT or AH group with the PTC group, ^§^The portion of the patients treated with levothyroxine or anti-thyroid drugs, ^∥^Comparison between the absence and the presence of calcification.

###### Clinical, Biochemical, and Sonographic Characteristics of the FLT Group, Compared with the PTC Group, According to Nodule Size
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                                             Nodule size \<10 mm   Nodule size ≤10 mm                                       
  ------------------------------------------ --------------------- -------------------- --------- ------------ ------------ -------
  Clinical and biochemical characteristics                                                                                  
   Age (yrs)                                 54.0±11.3             51.6±11.4            0.281     54.9±11.9    54.2±11.3    0.815
   Sex (male:female)                         4:41                  3:63                 0.355     10:0         29:5         0.573
   Current medications (%)^\*^               3 (6.7)               1 (1.5)              0.153     1 (10.0)     0 (0.0)      0.233
   T3 (ng/dL)                                156.3±43.5            147.5±35.1           0.284     120.3±20.3   155.5±32.4   0.012
   FreeT4 (ng/dL)                            1.4±1.2               1.4±1.2              0.978     0.8±0.3      1.8±1.8      0.001
   TSH (µIU/mL)                              5.7±11.2              1.9±1.4              0.033     4.8±6.7      1.8±1.2      0.044
   Tg-Ab positive (%)                        27 (64.3)             6 (9.1)              \<0.001   6 (60.0)     10 (29.4)    0.133
   TPO-Ab positive (%)                       23 (54.8)             12 (18.2)            \<0.001   5 (50.0)     10 (29.4)    0.271
   Nodule diameter (mm)                      6.0±2.0               6.1±1.6              0.858     14.4±0.7     14.4±0.5     0.553
  US characteristics                                                                                                        
   Shape                                                                                                                    
    Taller than wide                         25 (55.6)             48 (72.7)            0.061     3 (30.0)     8 (23.5)     0.692
    Wider than tall                          20 (44.4)             18 (27.3)                      7 (70.0)     26 (76.5)    
   Margin                                                                                                                   
    Well-defined                             0 (0.0)               0 (0.0)              1.000     0 (0.0)      1 (2.9)      1.000
    Ill-defined                              45 (100.0)            66 (100.0)                     10 (100.0)   33 (97.1)    
   Echogenicity                                                                                                             
    Marked hypoechoic                        5 (11.1)              1 (1.5)              0.045     0 (0.0)      3 (8.8)      0.668
    Hypoechoic                               36 (80.0)             63 (95.9)                      9 (90.0)     28 (82.4)    
    Isoechoic                                2 (4.4)               1 (1.5)                        1 (10.0)     1 (2.9)      
    Hyperechoic                              2 (4.4)               0 (0.0)                        0 (0.0)      1 (2.9)      
    Mixed echoic                             0 (0.0)               1 (1.5)                        0 (0.0)      1 (2.9)      
   Calcification                                                                                                            
    Present                                  10 (22.2)             22 (33.3)            0.204     1 (10.0)     20 (58.8)    0.010
    Absent                                   35 (77.8)             44 (66.7)                      9 (90.0)     14 (41.2)    
   Cystic degeneration                                                                                                      
    Present                                  0 (0.0)               1 (1.5)              0.407     0 (0.0)      1 (2.9)      1.000
    Absent                                   45 (100.0)            65 (98.5)                      10 (100.0)   33 (97.1)    
   DTD pattern                                                                                                              
    Present                                  36 (80.0)             5 (7.6)              \<0.001   7 (70.0)     4 (11.8)     0.001
    Absent                                   9 (20.0)              61 (92.4)                      3 (30.0)     30 (88.2)    

PTC, papillary thyroid cancer; FLT, focal lymphocytic thyroiditis; TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody; DTD pattern, \"diffuse thyroid disease\" pattern on US; US, ultrasound.

Data are mean±SD or number of patients (%). *p* value by Student\'s t-test or Mann-Whitney U test for continuous variables and χ^2^-test or Fisher exact test for categorical variables.

^\*^The portion of the patients treated with levothyroxine or anti-thyroid drugs.

###### Univariate and Multivariate Analysis among Groups
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                              Univariate   Multivariate                                      
  --------------------------- ------------ --------------- --------- -------- -------------- ---------
  FLT vs. PTC                                                                                
   TSH\>2.50 µIU/mL           4.462        2.169-9.178     \<0.001                           
   Tg-Ab positivity           9.118        4.191-19.841    \<0.001   3.036    1.060-8.696    0.039
   TPO-Ab positivity          4.136        2.010-8.514     \<0.001                           
   Taller than wider          0.815        0.421-1.576     0.543                             
   Absence of calcification   2.897        1.340-6.261     0.007     3.781    1.182-12.097   0.025
   Presence of DTD pattern    36.231       14.192-92.500   \<0.001   24.519   8.597-69.925   \<0.001
  AH vs. PTC                                                                                 
   TSH\>2.50 µIU/mL           0.917        0.404-2.077     0.835                             
   Tg-Ab positivity           0.735        0.283-1.909     0.527                             
   TPO-Ab positivity          0.425        0.161-1.122     0.084     0.427    0.157-1.163    0.096
   Taller than wider          0.292        0.146-0.587     0.001     0.288    0.140-0.590    0.001
   Absence of calcification   0.700        0.367-1.336     0.280                             
   Presence of DTD pattern    1.145        0.386-3.395     0.808                             

FLT, focal lymphocytic thyroiditis; PTC, papillary thyroid cancer; AH, adenomatous hyperplasia; TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody; DTD pattern, \"diffuse thyroid disease\" pattern on US; OR, odds ratio; CI, confidence interval; US, ultrasound.

###### Univariate and Multivariate Analysis between the FLT Group and the PTC Group According to Nodule Size
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                              Univariate   Multivariate                                        
  --------------------------- ------------ ---------------- --------- -------- --------------- ---------
  Nodule size\<10 mm                                                                           
   TSH\>2.50 µIU/mL           3.883        1.692-8.911      0.001                              
   Tg-Ab positivity           18.99        6.298-51.441     \<0.001   4.985    1.201-20.689    0.027
   TPO-Ab positivity          5.447        2.278-13.029     \<0.001                            
   Taller than wider          0.469        0.211-1.043      0.063     0.337    0.091-1.243     0.102
   Absence of calcification   1.750        0.734-4.174      0.207                              
   Presence of DTD pattern    48.800       15.172-156.958   \<0.001   29.265   7.788-109.970   \<0.001
  Nodule size≥10 mm                                                                            
   TSH\>2.50 µIU/mL           7.000        1.498-32.720     0.013                              
   Tg-Ab positivity           3.600        0.832-15.572     0.086                              
   TPO-Ab positivity          2.400        0.567-10.155     0.234                              
   Taller than wider          1.393        0.290-6.679      0.679                              
   Absence of calcification   12.857       1.459-113.278    0.021     12.487   1.093-142.673   0.042
   Presence of DTD pattern    17.500       3.171-96.575     0.001     17.079   2.464-118.388   0.004

FLT, focal lymphocytic thyroiditis; PTC, papillary thyroid cancer; TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody; DTD pattern, \"diffuse thyroid disease\" pattern on US; OR, odds ratio; CI, confidence interval; US, ultrasound.

###### Predictor Model of FLT from PTC Based on Individual or Combined Variables
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                                                                            Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  ------------------------------------------------------------------------- ----------------- ----------------- --------- ---------
  Tg-Ab positivity                                                          63                84                67        82
  Absence of calcification                                                  80                42                43        79
  Presence of DTD pattern                                                   79                91                83        88
  Tg-Ab positivity and absence of calcification                             51                92                78        77
  Tg-Ab positivity and presence of DTD pattern                              55                96                88        79
  Absence of calcification and presence of DTD pattern                      65                96                90        83
  Tg-Ab positivity, absence of calcification, and presence of DTD pattern   45                99                96        77

FLT, focal lymphocytic thyroiditis; PTC, papillary thyroid cancer; Tg-Ab, thyroglobulin antibody; DTD pattern, \"diffuse thyroid disease\" pattern on US; PPV, positive predictive value; NPV, negative predictive value; US, ultrasound.
